Retrospective Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 14, 2017; 23(2): 297-305
Published online Jan 14, 2017. doi: 10.3748/wjg.v23.i2.297
3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy
Chang Hun Lee, In Hee Kim, Jin Chang Moon, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim, Jae Do Yang, Hee Chul Yu
Chang Hun Lee, In Hee Kim, Jin Chang Moon, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim, Division of Gastroenterology, Department of Internal Medicine, Chonbuk National University Medical School and Hospital, Jeonju 561-180, South Korea
Jae Do Yang, Hee Chul Yu, Department of Surgery, Chonbuk National University Medical School and Hospital, Jeonju 561-180, South Korea
Author contributions: Kim IH designed the study; Lee CH and Moon JC collected and analyzed the data; Seo SY, Kim SH, Kim SW and Lee SO drafted the manuscript; Lee CH and Kim IH revised the manuscript; Yang JD and Yu HC offered the technical or material support; Lee ST and Kim DG supervised the study; all authors have read and approved the final version to be published.
Supported by Chonbuk National University 2013.
Institutional review board statement: This study was conducted in compliance with the World Medical Association Declaration of Helsinki and was approved by the Ethics Committee at Chonbuk National University Hospital. (IRB number: CUH-2016-07-026-001).
Informed consent statement: Due to the retrospective nature of the study, patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to receive examination of abdominal computed tomography by written informed consent.
Conflict-of-interest statement: The authors disclose no competing interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: In Hee Kim, MD, PhD, Department of Internal Medicine, Chonbuk National University Medical School, San 2-20 Geumam-dong, Deokjin-gu, Jeonju, Jeonbuk 561-180, South Korea. ihkimmd@jbnu.ac.kr
Telephone: +82-63-2501677
Received: October 4, 2016
Peer-review started: October 7, 2016
First decision: November 9, 2016
Revised: November 22, 2016
Accepted: December 8, 2016
Article in press: December 8, 2016
Published online: January 14, 2017
Processing time: 100 Days and 5.2 Hours
Core Tip

Core tip: Liver volume change may represent the hepatic functional and regenerative capacity. We inspected the effect of oral nucleos(t)ide analogues (NUCs) on liver volume in patients with hepatitis B virus-related cirrhosis. The result showed the increase in liver volume during two years of NUCs therapy and the volume increase was shown both in compensated and decompensated cirrhosis. The increase in liver volume was well correlated with several markers representing hepatic functional status. More volume increase may be attained regarding aggressive damage at baseline and marked improvement during the treatment period. Our data support the reversal of fibrosis and enhancement of liver regeneration of damaged liver in patients with liver cirrhosis after the treatment with NUCs.